AbbVie (ABBV) Tops Q1 EPS by 8c, Raises FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
AbbVie (ABBV) Highlights New Investigational Data for Elagolix at 2018 ACOG Meetings
April 27, 2018 8:10 AM EDTAbbVie (NYSE: ABBV) today announced that data for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist, will be presented at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting in Austin, TX.
"We strive to improve care for women living with endometriosis and uterine fibroids," said Dawn Carlson, M.D., M.P.H., vice president, general medicine development. "These presentations highlight safety and efficacy data for elagolix and... More
Abbvie (ABBV) PT Raised to $101 at Deutsche Bank
April 27, 2018 7:49 AM EDTDeutsche Bank raised its price target on Abbvie (NYSE: ABBV) to $101.00 (from $100.00) while maintaining a Hold rating.
... MoreAbbVie (ABBV) Plans $7.5B Tender Offer
April 26, 2018 7:52 AM EDTWith earnings, AbbVie (NYSE: ABBV) said it plans to commence a tender offer to purchase for cash up to $7.5 billion in value of shares of its common stock through a modified "Dutch auction" tender offer at a specified price range to be determined.... More
